The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Primaquine-Induced Acute Liver Failure

Primaquine 과복용 후 발생한 간부전 1예

  • Jun, Mi-Jung (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Danbi (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Yun-Sik (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Eun-Jin (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Gong, Eun-Jeoung (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chung, Young-Hwa (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 전미정 (울산대학교 의과대학 서울아산병원 내과) ;
  • 이단비 (울산대학교 의과대학 서울아산병원 내과) ;
  • 최윤식 (울산대학교 의과대학 서울아산병원 내과) ;
  • 김은진 (울산대학교 의과대학 서울아산병원 내과) ;
  • 공은정 (울산대학교 의과대학 서울아산병원 내과) ;
  • 정영화 (울산대학교 의과대학 서울아산병원 내과)
  • Received : 2013.05.29
  • Accepted : 2013.07.22
  • Published : 2014.01.01
⟨ Previous Next ⟩

Abstract

Primaquine was approved for treatment of malaria in 1952 by the United States Food and Drug Administration (FDA). It has remained the only FDA-licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. It is associated with serious hazards and side effects, such as hemolytic anemia and methemoglobinemia. However, there is no report of primaquine causing liver injury in Korea. We describe a case of acute liver failure following primaquine overdose in a 19-year-old man.

항말라리아 치료제로 널리 사용되고 있는 primaquine에 대한 다양한 부작용은 많은 보고들을 통해서 알려져 있다. 그러나 약인성 간손상, 간부전으로 진행한 예는 국외 1예를 제외하고 국내에서는 그동안 보고되지 않았다. 저자들은 primaquine 과복용 후 간수치 이상, 프로트롬빈 시간 연장 및 의식장애와 같은 간부전이 발생한 증례를 경험하였기에 문헌고찰과 함께 국내 최초로 보고하는 바이다.

Keywords

References

  1. Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J 2011;10:351. https://doi.org/10.1186/1475-2875-10-351
  2. Thornsvard CT, Guider BA, Kimball DB. An unusual reaction to chloroquine-primaquine. JAMA 1976;235:1719-1720. https://doi.org/10.1001/jama.1976.03260420035025
  3. Lobel HO, Coyne PE, Rosenthal PJ. Drug overdoses with antimalarial agents: prescribing and dispensing errors. JAMA 1998;280:1483. https://doi.org/10.1001/jama.280.17.1483
  4. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330. https://doi.org/10.1016/0895-4356(93)90101-6
  5. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol 2009;241:14-22. https://doi.org/10.1016/j.taap.2009.07.012
  6. Bangchang KN, Karbwang J, Back DJ. Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 1992;44:587-590. https://doi.org/10.1016/0006-2952(92)90453-P
  7. Vasquez-Vivar J, Augusto O. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J Biol Chem 1992;267:6848-6854.
  8. Schmidt LH, Alexander S, Allen L, Rasco J. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob Agents Chemother 1977;12:51-60. https://doi.org/10.1128/AAC.12.1.51
  9. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000;109:109-113. https://doi.org/10.1016/S0002-9343(00)00461-7
  10. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003;82:392-406. https://doi.org/10.1097/01.md.0000101573.54295.bd

Cited by

  1. A Case of Methemoglobinemia Caused by Primaquine vol.92, pp.1, 2017, https://doi.org/10.3904/kjm.2017.92.1.94